Cargando…

Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice

The purpose of this work was to use various molecular imaging techniques to non-invasively assess GSK2849330 (anti HER3 ADCC and CDC enhanced ‘AccretaMab’ monoclonal antibody) pharmacokinetics and pharmacodynamics in human xenograft tumor-bearing mice. Immuno-PET biodistribution imaging of radiolabe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsaid, Hasan, Skedzielewski, Tinamarie, Rambo, Mary V., Hunsinger, Kristen, Hoang, Bao, Fieles, William, Long, Edward R., Tunstead, James, Vugts, Danielle J., Cleveland, Matthew, Clarke, Neil, Matheny, Christopher, Jucker, Beat M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407619/ https://www.ncbi.nlm.nih.gov/pubmed/28448604 http://dx.doi.org/10.1371/journal.pone.0176075

Ejemplares similares

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors
por: Gan, Hui K., et al.
Publicado: (2021)

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
por: Blackwell, Christina, et al.
Publicado: (2016)

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity
por: Kato, Yukinari, et al.
Publicado: (2015)

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
por: Natsume, Akito, et al.
Publicado: (2009)

In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
por: Aweda, Tolulope A., et al.
Publicado: (2022)

Immuno-PET Monitoring of CD8(+) T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a (89)Zr Anti-CD8(+) Mouse Minibody in EMT6 Syngeneic Tumor Mouse
por: Alsaid, Hasan, et al.
Publicado: (2022)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
por: Oppenheim, D E, et al.
Publicado: (2014)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Induction of ADCC by a folic acid–mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells
por: Tagawa, Hiroshi, et al.
Publicado: (2020)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces ADCC and apoptosis in HER2-positive high grade DCIS
por: Giannos, J, et al.
Publicado: (2000)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
por: Dixon, Kate J., et al.
Publicado: (2021)

The Yin and Yang of ADCC-Mediating Antibodies
por: Robert-Guroff, Marjorie
Publicado: (2016)

Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles
por: Arvizo, Rochelle R., et al.
Publicado: (2011)

Development of a Macrophage-Based ADCC Assay
por: Uccellini, Melissa B., et al.
Publicado: (2021)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles
por: Álamo, Patricia, et al.
Publicado: (2020)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Cdc6 licenses tumor growth
por: Leslie, Mitch
Publicado: (2011)

The Contribution of IgG Glycosylation to Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) in Hashimoto’s Thyroiditis: An in Vitro Model of Thyroid Autoimmunity
por: Ząbczyńska, Marta, et al.
Publicado: (2020)

ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011)

γδT cells are ADCC effectors in elite HIV controllers
por: Poonia, Bhawna, et al.
Publicado: (2010)

ADCC: An underappreciated correlate of cross-protection against influenza?
por: de Vries, Rory D., et al.
Publicado: (2023)

Cdc6 degradation requires phosphodegron created by GSK-3 and Cdk1 for SCF(Cdc4) recognition in Saccharomyces cerevisiae
por: Al-Zain, Amr, et al.
Publicado: (2015)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans
por: Thorneloe, Kevin S., et al.
Publicado: (2019)

Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice
por: Snehalatha, Movva, et al.
Publicado: (2013)

CDC20 maintains tumor initiating cells
por: Xie, Qi, et al.
Publicado: (2015)

CDC7 Expression in Selected Odontogenic Tumors
por: Jaafari-Ashkavandi, Zohreh, et al.
Publicado: (2022)

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies
por: Lallemand, Christophe, et al.
Publicado: (2017)

Biodistribution and in Vivo Activities of Tumor-Associated Macrophage-Targeting Nanoparticles Incorporated with Doxorubicin
por: Niu, Mengmeng, et al.
Publicado: (2014)

Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting
por: Liu, Hui, et al.
Publicado: (2015)

CPPs to the Test: Effects on Binding, Uptake and Biodistribution of a Tumor Targeting Nanobody
por: Collado Camps, Estel, et al.
Publicado: (2021)

FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients
por: Romano, Emanuela, et al.
Publicado: (2014)

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
por: Giraudet, Anne-Laure, et al.
Publicado: (2018)

The Role of GSK3β in T Lymphocytes in the Tumor Microenvironment
por: Dimou, Anastasios, et al.
Publicado: (2020)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b9ujopr9pb1pi5q2vi41ka9ona